Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 1999; 82(S 01): 60-61
DOI: 10.1055/s-0037-1615554
DOI: 10.1055/s-0037-1615554
Commentaries
Lipid Lowering Therapy and Stabilization of Atherosclerotic Plaques
Further Information
Publication History
Publication Date:
14 December 2017 (online)
Summary
Lipid-lowering therapy leads to a great reduction of cardiovascular complications, but has almost no effect on the degree of stenosis of coronary arteries. These and other studies have lead to a new paradigm of coronary artery disease, i. e. clinical prognosis is not only determined by the extent of a single stenosis, but mainly by the number and structure of atherosclerotic plaques. Rupture of an instable or vulnerable plaque, characterized by a large lipid-rich central core, inflammatory cells, and a thin fibrous cap, causes sudden thrombus formation and thereby acute coronary syndromes. There is accumulating evidence that cholesterol lowering can result in plaque stabilization and improvement of endothelial dysfunction.
-
References
- 1 Watts GF, Burke V. Lipid-lowering trials in the primary and secondary prevention of coronary heart disease: new evidence, implications and outstanding issues. Curr Opin Lipidol 1996; 7: 341-55.
- 2 Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. JAMA 1997; 278: 313-21.
- 3 Brown BG, Zhao X-Q, Sacco BE, Albers JJ. Lipid lowering and plaque regression and new insights into prevention of plaque disruption and clinical events in coronary heart disease. Circulation 1993; 87: 1781-91.
- 4 O'keefe Jr. JH, Conn RD, Lavie Jr. CJ, Maeman TM. The new paradigm for coronary artery disease: altering risk factors, atherosclerotic plaques and clinical prognosis. Mayo Clin Proc 1996; 71: 957-65.
- 5 Kannel WB. Incidence, prevalence, and mortality of coronary artery disease. In: Atherosclerosis and Coronary Artery Disease. Fuster V, Ross R, Topol EJ. eds. Philadelphia: Lippincott-Raven Publishers 1996; 1: 13-24.
- 6 Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White lecture 1995. Circulation 1996; 94: 2013-20.
- 7 Mann JM, Davies MJ. Vulnerable plaque. Relation of characteristics to degree of stenosis in human coronary syndrome. Circulation 1995; 94: 928-31.
- 8 Libby P. Molecular basis of the acute coronary syndrome. Circulation 1995; 91: 2844-50.
- 9 Guyton JR, Klemp KF. Development of the lipid-rich core in human atherosclerosis. Arterioscler Thromb Vasc Biol 1996; 16: 4-11.
- 10 Falke E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-71.
- 11 Stary HC, Blankenhorn DH, Chandler BA, Glagov S, Insul Jr. W, Richardson M, Rosenfeld ME, Schaffer SA, Schwarz CJ, Wagner WD. et al. A definition of the intima of human arteries and of its atherosclerosis-prone regions. Circulation 1992; 85: 391-405.
- 12 Stary HC, Chandler BA, Glagov S, Guyton JR, Insul Jr. W, Rosenfeld ME, Schaffer SA, Schwarz CJ, Wagner WD, Wissler RW. A definition of initial fatty streak, and intermediate lesions of atherosclerosis. Arterioscler Thromb 1994; 14: 840-56.
- 13 Stary HC, Chandler BA, Dinsmure RE, Fuster V, Glagov S, Insul Jr. W, Rosenfeld ME, Schwarz CF, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. Circulation 1995; 92: 1355-74.
- 14 Kinlay S, Selwyn AP, Delagrange D, Creager MA, Libby P, Ganz P. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points. Curr Opin Lipidol 1996; 7: 389-97.
- 15 Vaughan CJ, Murphy MB, Buckey BM. Statins do more than just lower cholesterol. Lancet 1996; 348: 1079-82.
- 16 O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-31.
- 17 Tamai O, Mastsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilation in hypercho-lesterolemic humans. Circulation 1997; 95: 76-82.
- 18 Andrews TC, Raby K, Barry J, Naimi CL, Allred E, Ganz P, Selwyn AP. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997; 95: 324-8.
- 19 Müller-Wieland D, Kolzka J, Krone W. Stabilization of atherosclerotic plaque during lipid lowering. Curr Opin Lipidol 1997; 8: 348-53.